Henlius Finds Global Partner For Ophthalmic Bevacizumab

Strikes Deal With Essex Bio-Technology For Biosimilar Avastin Rival

 
• By Dave Wallace

Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essex Bio-Technology for biosimilar bevacizumab to treat ophthalmic diseases.

Eye
Henlius and Essex will collaborate on the biosimilar for ophthalmic indications • Source: Shutterstock

More from Biosimilars

More from Products